Potent inhibitor of cyclin-dependent kinases (CDKs). Induces apoptosis in certain tumor cells. Interacts with multidrug resistance protein 1 (MRP1).
Product Details
Alternative Name: | Alvocidib, (-)-2-(2-Chlorophenyl)-5,7-dihydroxy-8-[(3R,4S)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one |
|
Formula: | C21H20ClNO5 |
|
MW: | 401.8 |
|
Source: | Synthetic. |
|
CAS: | 146426-40-6 |
|
MI: | 14: 4094 |
|
Purity: | ≥97% (HPLC) |
|
Identity: | Identity determined by 1H-NMR. |
|
Appearance: | Yellow powder. |
|
Solubility: | Soluble in chloroform; slightly soluble in water. |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | +4°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
Neutrophil Extracellular Trap Formation Is Independent of De Novo Gene Expression: G. Sollberger, et al.; PLoS One
11, e0157454 (2016),
Application(s): Inhibition,
Abstract;
Full Text
Germline gain-of-function mutations in AFF4 cause a developmental syndrome functionally linking the super elongation complex and cohesin: K. Izumi, et al.; Nat. Genet.
47, 338 (2015),
Application(s): Cell Culture,
Abstract;
Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors: C. Sekine, et al.; J. Immunol.
180, 1954 (2008),
Abstract;
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL: T.E. Fandy, et al.; Cancer Chemother. Pharmacol.
60, 313 (2007),
Abstract;
Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics: A. Pumrery, et al.; Curr. Pharm. Des.
12, 1949 (2006),
Abstract;
Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells: U. Raju, et al.; Cancer Res.
63, 3263 (2003),
Abstract;
Full Text
Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia: S. Kitada, et al.; Blood
96, 393 (2000),
Abstract;
Full Text
Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials: A.M. Senderowicz; Invest. New Drugs
17, 313 (1999), (Review),
Abstract;
Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein: J.B. Schnier, et al.; FEBS Lett.
454, 100 (1999),
Abstract;
Potent interaction of flavopiridol with MRP1: J.H. Hooijberg, et al.; Br. J. Cancer
81, 269 (1999),
Abstract;
Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells: S. Brüsselbach, et al.; Int. J. Cancer
77, 146 (1998),
Abstract;
Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53: J.C. Byrd, et al.; Blood
92, 3804 (1998),
Abstract;
Full Text
Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts: F. Arguello, et al.; Blood
91, 2482 (1998),
Abstract;
Full Text
Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells: M. Drees, et al.; Clin. Cancer Res.
3, 273 (1997),
Abstract;
Full Text
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines: A. König, et al.; Blood
90, 4307 (1997),
Abstract;
Full Text
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells: B.A. Carlson, et al.; Cancer Res.
56, 2973 (1996),
Abstract;
Full Text
Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells: K.C. Bible & S.H. Kaufmann; Cancer Res.
56, 4856 (1996),
Abstract;
Full Text
Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase: W.F. Jr. De Azevedo, et al.; PNAS
93, 2735 (1996),
Abstract;
Full Text